STOCK TITAN

Psychemedics Corporation Launches New Ketamine Hair Testing Service

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Psychemedics (NASDAQ: PMD), a leader in hair testing, has launched a new ketamine hair testing service. This innovative solution offers a 90-day detection window, non-invasive collection, and high accuracy. Key features include:

  • Long detection window up to 90 days
  • Non-invasive and convenient collection process
  • High sensitivity and specificity
  • Integration with existing multi-drug panels
  • Applicability across various industries

The service aims to address the growing concern of ketamine abuse in workplaces, educational institutions, and law enforcement. CEO Brian Hullinger emphasized the company's commitment to providing reliable drug testing solutions for maintaining safe environments.

Psychemedics (NASDAQ: PMD), leader nei test sui capelli, ha lanciato un nuovo servizio di test sui capelli per la ketamina. Questa soluzione innovativa offre una finestra di rilevamento di 90 giorni, un processo di raccolta non invasivo e un'alta precisione. Le caratteristiche principali includono:

  • Finestra di rilevamento fino a 90 giorni
  • Processo di raccolta non invasivo e conveniente
  • Alta sensibilità e specificità
  • Integrazione con i pannelli multi-droga esistenti
  • Applicabilità in vari settori

Il servizio mira a rispondere alla crescente preoccupazione per l'abuso di ketamina in luoghi di lavoro, istituzioni educative e forze dell'ordine. Il CEO Brian Hullinger ha sottolineato l'impegno dell'azienda nel fornire soluzioni affidabili per i test sui droghe al fine di mantenere ambienti sicuri.

Psychemedics (NASDAQ: PMD), un líder en pruebas de cabello, ha lanzado un nuevo servicio de pruebas de cabello para ketamina. Esta solución innovadora ofrece una ventana de detección de 90 días, recolección no invasiva y alta precisión. Las características clave incluyen:

  • Ventana de detección de hasta 90 días
  • Proceso de recolección no invasivo y conveniente
  • Alta sensibilidad y especificidad
  • Integración con paneles de múltiples drogas existentes
  • Aplicabilidad en diversas industrias

El servicio tiene como objetivo abordar la creciente preocupación por el abuso de ketamina en el lugar de trabajo, instituciones educativas y fuerzas del orden. El CEO Brian Hullinger enfatizó el compromiso de la empresa de proporcionar soluciones confiables de pruebas de drogas para mantener entornos seguros.

Psychemedics (NASDAQ: PMD), 모발 검사 분야의 선두주자인, 새로운 케타민 모발 검사 서비스를 출시하였습니다. 이 혁신적인 솔루션은 90일 감지 기간, 비침습적인 채취 방법 및 높은 정확성을 제공합니다. 주요 특징은 다음과 같습니다:

  • 최대 90일까지의 긴 감지 기간
  • 비침습적이며 편리한 채취 과정
  • 높은 민감도와 특이도
  • 기존의 다약물 검사 패널과의 통합
  • 다양한 산업에 걸친 적용 가능성

이 서비스는 직장, 교육 기관 및 법 집행 기관에서의 케타민 남용에 대한 우려를 해결하는 것을 목표로 하고 있습니다. CEO 브라이언 헐린저는 안전한 환경 유지를 위한 신뢰할 수 있는 약물 검사 솔루션을 제공하겠다는 회사의 의지를 강조했습니다.

Psychemedics (NASDAQ: PMD), un leader dans les tests capillaires, a lancé un nouveau service de test capillaire pour la kétamine. Cette solution innovante offre une fenêtre de détection de 90 jours, un processus de collecte non invasif et une grande précision. Les caractéristiques clés incluent :

  • Longue fenêtre de détection jusqu'à 90 jours
  • Processus de collecte non invasif et pratique
  • Haute sensibilité et spécificité
  • Intégration avec des panneaux de multidétection existants
  • Applicabilité dans divers secteurs

Le service vise à répondre à la préoccupation croissante concernant l'abus de kétamine dans les lieux de travail, les établissements d'enseignement et les forces de l'ordre. Le PDG Brian Hullinger a souligné l'engagement de l'entreprise à fournir des solutions de test de drogue fiables pour maintenir des environnements sûrs.

Psychemedics (NASDAQ: PMD), ein führendes Unternehmen im Bereich Haartests, hat einen neuen Ketamintestservice eingeführt. Diese innovative Lösung bietet ein Detektionsfenster von 90 Tagen, eine nicht-invasive Sammlung und hohe Genauigkeit. Zu den Hauptmerkmalen gehören:

  • Langfristiges Detektionsfenster von bis zu 90 Tagen
  • Nicht-invasive und bequeme Sammlung
  • Hohe Sensitivität und Spezifität
  • Integration in bestehende Mehrfachdrogentests
  • Anwendbarkeit in verschiedenen Branchen

Der Service zielt darauf ab, der wachsenden Besorgnis über den Missbrauch von Ketamin am Arbeitsplatz, in Bildungseinrichtungen und bei Strafverfolgungsbehörden gerecht zu werden. CEO Brian Hullinger betonte das Engagement des Unternehmens, zuverlässige Drogenprüfungs- lösungen zur Aufrechterhaltung sicherer Umgebungen zu bieten.

Positive
  • Introduction of new ketamine hair testing service expanding product portfolio
  • Long detection window of up to 90 days, offering comprehensive drug use history
  • Non-invasive and convenient testing method, potentially increasing adoption
  • High sensitivity and specificity, minimizing false positives and negatives
  • Integration capability with existing multi-drug panels, enhancing overall testing offerings
Negative
  • None.

Psychemedics' launch of ketamine hair testing is a significant advancement in drug detection technology. The 90-day detection window vastly improves upon traditional methods, offering a more comprehensive view of drug use patterns. This extended timeframe is important for identifying chronic or intermittent ketamine use, which shorter-term tests might miss. The high sensitivity and specificity of the test address a critical need in the medical and legal fields for accurate, reliable ketamine detection. However, it's important to note that while this test enhances detection capabilities, it doesn't directly address the underlying issues of ketamine abuse or provide treatment solutions. The impact on public health and workplace safety could be substantial, but the effectiveness will depend on how organizations implement and act on the test results.

The introduction of ketamine hair testing by Psychemedics represents a strategic market expansion in the drug testing industry. With the rising concern over ketamine abuse, this service addresses a growing demand from employers, schools and law enforcement agencies. The ability to integrate this test into existing multi-drug panels could drive increased adoption and potentially boost Psychemedics' revenue streams. However, the market impact will depend on factors such as pricing strategy, regulatory acceptance and competition from other testing methods. While this launch positions Psychemedics as an innovator in the field, investors should monitor the rate of adoption and any potential regulatory challenges that may arise. The company's success will hinge on its ability to effectively market this new service and maintain its technological edge in a rapidly evolving industry.

Psychemedics' new ketamine hair testing service could potentially drive revenue growth for the company. As a NASDAQ-listed entity (PMD), this product launch may positively impact the stock price if it gains traction in the market. The expansion of their testing portfolio addresses a growing niche, which could lead to increased market share and client base expansion. However, investors should consider that the financial impact may not be immediate, as adoption rates and market acceptance will take time to materialize. It's important to monitor upcoming quarterly reports for indications of revenue contribution from this new service. Additionally, potential R&D and marketing expenses associated with the launch could impact short-term profitability. While the news is promising, a balanced view would consider both the growth potential and the execution risks in bringing this new product to market.

DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing method marks a significant advancement in the detection and prevention for a drug-free workplace and community.

Ketamine, a powerful dissociative anesthetic and emerging drug of abuse, poses a growing concern for employers, educators, and law enforcement agencies. With the introduction of this new testing service, Psychemedics aims to equip organizations with the tools needed to identify and address ketamine use effectively.

Key Features and Benefits of Ketamine Hair Testing

  1. Long Detection Window: Unlike traditional drug testing methods, hair analysis can detect ketamine use for up to 90 days, providing a comprehensive overview of an individual’s drug use history.
  2. Non-Invasive and Convenient: The hair collection process is simple and noninvasive and can be performed without the need for specialized facilities, making it ideal for various testing environments.
  3. High Sensitivity and Specificity: Utilizing advanced technology, Psychemedics’ ketamine hair test ensures highly accurate results, minimizing the risk of false positives and negatives.
  4. Comprehensive Drug Panel: This new service can be integrated into existing multi-drug panels offered by Psychemedics, allowing for a broad-spectrum approach to drug testing.
  5. Support for Various Industries: The ketamine hair test is designed to meet the needs of diverse sectors, including workplace safety programs, educational institutions, rehabilitation centers, law enforcement agencies, and many others.

“We are thrilled to introduce ketamine hair testing as part of our commitment to delivering the most reliable and comprehensive drug testing solutions,” said Brian Hullinger, CEO and President of Psychemedics. “This new offering underscores our dedication to innovation and our mission to support organizations in maintaining safe and drug-free environments.”

Psychemedics’ ketamine hair testing service is now available to clients and partners. For more information about this new service or to schedule a consultation, please contact Psychemedics at info@psychemedics.com or visit our website at https://www.psychemedics.com.

About Psychemedics 

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com 


FAQ

What is the new service launched by Psychemedics (PMD) in August 2024?

Psychemedics (PMD) launched a new ketamine hair testing service in August 2024, offering a 90-day detection window for ketamine use.

How long can Psychemedics' (PMD) new ketamine hair test detect drug use?

Psychemedics' (PMD) new ketamine hair test can detect ketamine use for up to 90 days, providing a comprehensive overview of an individual's drug use history.

What industries can benefit from Psychemedics' (PMD) ketamine hair testing service?

Psychemedics' (PMD) ketamine hair testing service can benefit workplace safety programs, educational institutions, rehabilitation centers, law enforcement agencies, and other sectors requiring drug testing.

What are the key features of Psychemedics' (PMD) new ketamine hair test announced in 2024?

Key features of Psychemedics' (PMD) new ketamine hair test include a 90-day detection window, non-invasive collection, high sensitivity and specificity, and integration capability with existing multi-drug panels.

Psychemedics Corporation

NASDAQ:PMD

PMD Rankings

PMD Latest News

PMD Stock Data

13.51M
5.82M
22.62%
20.49%
0.52%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
ACTON